Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients

Scherrer, Alexandra U; Ledergerber, Bruno; von Wyl, Viktor; Böni, Jürg; Yerly Ferrillo, Sabine; Klimkait, Thomas; Cellerai, Cristina; Furrer, Hansjakob; Calmy, Alexandra; Cavassini, Matthias; Elzi, Luigia; Vernazza, Pietro L; Bernasconi, Enos; Günthard, Huldrych F

doi:10.1371/journal.pone.0037983

Scientific article

English

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients

ContributorsScherrer, Alexandra U; Ledergerber, Bruno; von Wyl, Viktor; Böni, Jürg; Yerly Ferrillo, Sabine; Klimkait, Thomas; Cellerai, Cristina; Furrer, Hansjakob; Calmy, Alexandra

; Cavassini, Matthias; Elzi, Luigia; Vernazza, Pietro L; Bernasconi, Enos; Günthard, Huldrych F

Published inPloS one, vol. 7, no. 6, e37983

Publication date2012

Abstract

Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naïve patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential.

Keywords

CD4 Lymphocyte Count
Drug Resistance, Viral/genetics
Female
HIV Infections/drug therapy/virology
HIV Protease/genetics
HIV Protease Inhibitors/pharmacology/therapeutic use
Humans
Male
Mutation
RNA, Viral/blood
Viral Load

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

VIH/SIDA (930)

Citation (ISO format)

SCHERRER, Alexandra U et al. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. In: PloS one, 2012, vol. 7, n° 6, p. e37983. doi: 10.1371/journal.pone.0037983

Article (Published version)

CC BY

Identifiers

PID : unige:31692
DOI : 10.1371/journal.pone.0037983
PMID : 22719859

Journal ISSN1932-6203

644views

257downloads

Creation03/12/2013 13:53:00

First validation03/12/2013 13:53:00

Update14/03/2023 20:40:32

Status update14/03/2023 20:40:31

Last indexation30/10/2024 15:11:29

Archive ouverte UNIGE

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients

Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naïve patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential.

Technical informations